Fast Five Quiz: Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD


January 11, 2022

Multiple myeloma is a plasma cell cancer characterized by proliferation of monoclonal plasma cells in bone marrow, leading to an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. The condition comprises an estimated 10% of hematologic cancers. The incidence rate of multiple myeloma has increased by 126% worldwide since 1990. Unlike other cancers that metastasize to the bone, up to 80% of patients with newly diagnosed multiple myeloma present with osteolytic lesions. Other events that can be present include anemia, hypercalcemia, and renal disfunction. Owing to the nature of the disease, most patients with multiple myeloma will have relapse, with subsequent lines of therapy adjusted according to prior treatment.

How would you approach the diagnosis, monitoring, and management of relapsed/refractory multiple myeloma? Check your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.